Differential susceptibility of HIV strains to innate immune factors in human cervical-vaginal secretions

Virus Adaptation and Treatment

Volumn 2, Issue 1, 2010, Pages 63-71

  Ghosh, Mimi ^a   Fahey, John V ^a   Wira, Charles R ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

CVL; HIV susceptibility

Indexed keywords

CYTOKINE; ESTRADIOL; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROGESTERONE;

ADAPTIVE IMMUNITY; DISEASE PREDISPOSITION; FEMALE GENITAL SYSTEM; HORMONAL REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MENSTRUAL CYCLE; NONHUMAN; PH; PROTECTION; REVIEW; SEXUALLY TRANSMITTED DISEASE; VAGINA SECRETION; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 77955436238     PISSN: None     EISSN: 11791624     Source Type: Book Series    
DOI: None     Document Type: Review

References (115)

1. UNAIDS 2009 Global Report; 2009. Available from: http://www.unaids.org/en/.
2. CDC. HIV/AIDS surveillance Report. AUDoHaHS. CDC. 2003;2003.
3. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmissionper coital act in monogamous, heterosexual, HIV-1-discordantcouples in Rakai, Uganda. Lancet. 2001;357(9263):1149-1153.
4. Ndesendo VM, Pillay V, Choonara YE, et al. A review of currentintravaginal drug delivery approaches employed for the prophylaxisof HIV/AIDS and prevention of sexually transmitted infections. AAPSPharm Sci Tech. 2008;9(2):505-520.
5. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmissionper coital act, by stage of HIV-1 infection, in Rakai, Uganda.J Infect Dis. 2005;191(9):1403-1409.
6. Quinn TC, Wawer MJ, Sewankambo N, et al; Rakai Project StudyGroup. Viral load and heterosexual transmission of human immunodeficiencyvirus type 1. N Engl J Med. 2000;342(13):921-929.
7. Colfax GN, Buchbinder SP, Cornelisse PG, et al. Sexual risk behaviorsand implications for secondary HIV transmission during and afterHIV seroconversion. AIDS. 2002;16(11):1529-1535.
8. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpessimplex virus-2 on HIV-1 acquisition and transmission: a review oftwo overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35(5):435-445.
9. Kaul R, Pettengell C, Sheth PM, et al. The genital tract immunemilieu: an important determinant of HIV susceptibility and secondarytransmission. J Reprod Immunol. 2008;77(1):32-40.
10. Wald A, Link K. Risk of human immunodeficiency virus infectionin herpes simplex virus type 2-seropositive persons: a meta-analysis.J Infect Dis. 2002;185(1):45-52.
11. Wira CR, Fahey JV. A new strategy to understand how HIV infectswomen: identification of a window of vulnerability during themenstrual cycle. AIDS. 2008;22(15):1909-1917.
12. Chakraborty H, Sen PK, Helms RW, et al. Viral burden in genitalsecretions determines male-to-female sexual transmission of HIV-1:a probabilistic empiric model. AIDS. 2001;15(5):621-627.
13. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification andcharacterization of transmitted and early founder virus envelopes inprimary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105(21):7552-7557.
14. Asin SN, Fanger MW, Wildt-Perinic D, et al. Transmission of HIV-1by primary human uterine epithelial cells and stromal fibroblasts.J Infect Dis. 2004;190(2):236-245.
15. Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al. Inflammatorygenital infections mitigate a severe genetic bottleneck in heterosexualtransmission of subtype A and C HIV-1. PLoS Pathog. 2009;5(1):e1000274.
16. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. Innate andadaptive immunity in female genital tract: cellular responses andinteractions. Immunol Rev. 2005;206:306-335.
17. Kaushic C, Wira CR. IgA and reproductive tract immunity. In:Kaetzel C, editor. IgA and Reproductive Tract Immunity. New York:Kluwer Academic/Plenum; 2008:291-320.
18. Fletcher PS, Harman SJ, Boothe AR, Doncel GF, Shattock RJ.Preclinical evaluation of lime juice as a topical microbicide candidate.Retrovirology. 2008;5:3.
19. Ongradi J, Ceccherini-Nelli L, Pistello M, Specter S, Bendinelli M.Acid sensitivity of cell-free and cell-associated HIV-1: clinicalimplications. AIDS Res Hum Retroviruses. 1990;6(12):1433-1436.
20. Connor RI. Sensitivity of non-clade B primary HIV-1 isolates to mildlyacidic pH. J Acquir Immune Defic Syndr. 2006;43(4):499-501.
21. Spear GT, Zariffard MR, Cohen MH, Sha BE. Vaginal IL-8 levelsare positively associated with Candida albicans and inversely withlactobacilli in HIV-infected women. J Reprod Immunol. 2008;78(1):76-79.
22. Maher D, Wu X, Schacker T, Horbul J, Southern P. HIV binding, penetration, and primary infection in human cervicovaginal tissue.Proc Natl Acad Sci U S A. 2005;102(32):11504-11509.
23. Aflatoonian R, Fazeli A. Toll-like receptors in female reproductivetract and their menstrual cycle dependent expression. J ReprodImmunol. 2008;77(1):7-13.
24. Fazeli A, Bruce C, Anumba DO. Characterization of Toll-like receptorsin the female reproductive tract in humans. Hum Reprod. 2005;20(5):1372-1378.
25. Pioli PA, Amiel E, Schaefer TM, et al. Differential expression ofToll-like receptors 2 and 4 in tissues of the human female reproductivetract. Infect Immun. 2004;72(10):5799-5806.
26. Schaefer TM, Desouza K, Fahey JV, Beagley KW, Wira CR. Toll-likereceptor (TLR) expression and TLR-mediated cytokine/chemokineproduction by human uterine epithelial cells. Immunology. 2004;112(3):428-436.
27. Schaefer TM, Fahey JV, Wright JA, Wira CR. Innate immunity inthe human female reproductive tract: antiviral response of uterineepithelial cells to the TLR3 agonist poly(I:C). J Immunol. 2005;174(2):992-1002.
28. Fahey JV, Wright JA, Shen L, et al. Estradiol selectively regulatesinnate immune function by polarized human uterine epithelial cellsin culture. Mucosal Immunol. 2008;1(4):317-325.
29. King AE, Critchley HO, Kelly RW. Presence of secretory leukocyteprotease inhibitor in human endometrium and first trimester deciduasuggests an antibacterial protective role. Mol Hum Reprod. 2000;6(2):191-196.
30. King AE, Fleming DC, Critchley HO, Kelly RW. Differential expressionof the natural antimicrobials, beta-defensins 3 and 4, in human endometrium.J Reprod Immunol. 2003;59(1):1-16.
31. Quayle AJ, Porter EM, Nussbaum AA, et al. Gene expression, immunolocalization, and secretion of human defensin-5 in human femalereproductive tract. Am J Pathol. 1998;152(5):1247-1258.
32. Valore EV, Park CH, Quayle AJ, et al. Human b-defensin-1,an antimicrobial peptide of urogenital tissues. J Clin Invest. 1998;101:1633-1642.
33. Crane-Godreau MA, Wira CR. Effects of estradiol on lipopolysaccharideand Pam3Cys stimulation of CCL20/macrophage inflammatoryprotein 3 alpha and tumor necrosis factor alpha production by uterineepithelial cells in culture. Infect Immun. 2005;73(7):4231-4237.
34. Ghosh M, Shen Z, Schaefer TM, et al. CCL20/MIP3alpha is a novelanti-HIV-1 molecule of the human female reproductive tract. Am JReprod Immunol. 2009;62(1):60-71.
35. Cai R, Carpick B, Chun RF, Jeang KT, Williams BR. HIV-I TATinhibits PKR activity by both RNA-dependent and RNA-independentmechanisms. Arch Biochem Biophys. 2000;373(2):361-367.
36. Gatignol A, Laine S, Clerzius G. Dual role of TRBP in HIV replicationand RNA interference: viral diversion of a cellular pathway or evasionfrom antiviral immunity? Retrovirology. 2005;2:65.
37. Malmgaard L. Induction and regulation of IFNs during viral infections.J Interferon Cytokine Res. 2004;24(8):439-454.
38. Sen GC, Peters GA. Viral stress-inducible genes. Adv Virus Res. 2007;70:233-263.
39. Sen GC, Sarkar SN. The interferon-stimulated genes: targets of directsignaling by interferons, double-stranded RNA, and viruses. Curr TopMicrobiol Immunol. 2007;316:233-250.
40. Marsili G, Borsetti A, Sgarbanti M, et al. On the role of interferonregulatory factors in HIV-1 replication. Ann N Y Acad Sci. 2003;1010:29-42.
41. Givan AL, White HD, Stern JE, et al. Flow cytometric analysis ofleukocytes in the human female reproductive tract: comparison offallopian tube, uterus, cervix, and vagina. Am J Reprod Immunol.1997;38(5):350-359.
42. Eriksson M, Meadows SK, Wira CR, Sentman CL. Unique phenotypeof human uterine NK cells and their regulation by endogenousTGF-beta. J Leukoc Biol. 2004;76(3):667-675.
43. Smith JM, Wira CR, Fanger MW, Shen L. Human fallopian tubeneutrophils: a distinct phenotype from blood neutrophils. Am J ReprodImmunol. 2006;56:218-229.
44. Ochiel DO, Ghosh M, Fahey JV, Guyre PM, Wira CR. Human uterineepithelial cell secretions regulate dendritic cell differentiation andresponses to TLR ligands. J Leukoc Biol. In press 2010.
45. Pioli PA, Weaver LK, Schaefer TM, et al. Lipopolysaccharide-inducedIL-1 beta production by human uterine macrophages up-regulatesuterine epithelial cell expression of human beta-defensin 2. J Immunol.2006;176(11):6647-6655.
46. Sentman CL, Wira CR, Eriksson M. NK cell function in the human femalereproductive tract. Am J Reprod Immunol. 2007;57(2):108-115.
47. Mselle TF, Meadows SK, Eriksson M, et al. Unique characteristicsof NK cells throughout the human female reproductive tract. ClinImmunol. 2007;124(1):69-76.
48. Choudhury SR, Knapp LA. Human reproductive failure II: immunogeneticand interacting factors. Hum Reprod Update. 2001;7(2):135-160.
49. Kopcow HD, Eriksson M, Mselle TF, et al. Human decidual NK cellsfrom gravid uteri and NK cells from cycling endometrium are distinctNK cell subsets. Placenta. In press 2010.
50. Yao V, Platell C, Hall JC. Dendritic cells. ANZ J Surg. 2002;72(7):501-506.
51. Gupta P, Collins KB, Ratner D, et al. Memory CD4(+) T cells are theearliest detectable human immunodeficiency virus type 1 (HIV-1)-infectedcells in the female genital mucosal tissue during HIV-1 transmissionin an organ culture system. J Virol. 2002;76(19):9868-9876.
52. Mestecky J, Moldoveanu Z, Smith PD, Hel Z, Alexander RC. Mucosalimmunology of the genital and gastrointestinal tracts and HIV-1infection. J Reprod Immunol. 2009;83(1-2):196-200.
53. Moldoveanu Z, Mestecky J. Mucosal antibody responses to HIV.Methods Mol Biol. 2009;485:333-345.
54. Keller M, Guzman E, Hazrati E, et al. PRO 2000 elicits a declinein genital tract immune mediators without compromising intrinsicantimicrobial activity. AIDS. 2007;21:467-476.
55. Bingle CD, Vyakarnam A. Novel innate immune functions of thewhey acidic protein family. Trends Immunol. 2008;29(9):444-453.
56. Cole AM, Cole AL. Antimicrobial polypeptides are key anti-HIV-1effector molecules of cervicovaginal host defense. Am J ReprodImmunol. 2008;59(1):27-34.
57. Iqbal SM, Kaul R. Mucosal innate immunity as a determinant of HIVsusceptibility. Am J Reprod Immunol. 2008;59(1):44-54.
58. Ma G, Greenwell-Wild T, Lei K, et al. Secretory leukocyte proteaseinhibitor binds to annexin II, a cofactor for macrophage HIV-1infection. J Exp Med. 2004;200(10):1337-1346.
59. Py B, Basmaciogullari S, Bouchet J, et al. The phospholipidscramblases 1 and 4 are cellular receptors for the secretory leukocyteprotease inhibitor and interact with CD4 at the plasma membrane.PLoS One. 2009;4(3):e5006.
60. Weinberg A, Quinones-Mateu ME, Lederman MM. Role of humanbeta-defensins in HIV infection. Adv Dent Res. 2006;19(1):42-48.
61. Seidel A, Ye Y, de Armas LR, et al. Cyclic and acyclic defensinsinhibit human immunodeficiency virus type-1 replication by differentmechanisms. PLoS One. 2010;5(3):e9737.
62. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P. Alpha-defensinsblock the early steps of HIV-1 infection: interference with the bindingof gp120 to CD4. Blood. 2007;109(7):2928-2935.
63. Skott P, Lucht E, Ehnlund M, Bjorling E. Inhibitory function of secretoryleukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specificand varies with virus tropism. Oral Dis. 2002;8(3):160-167.
64. Ishikawa C, Tanabe H, Maemoto A, et al. Precursor processing ofhuman defensin-5 is essential to the multiple functions in vitro andin vivo. J Innate Immun. 2010;2:66-76.
65. Guyot N, Zani ML, Berger P, Dallet-Choisy S, Moreau T. Proteolyticsusceptibility of the serine protease inhibitor trappin-2 (pre-elafin):evidence for tryptase-mediated generation of elafin. Biol Chem. 2005;386(4):391-399.
66. Jokimaa V, Oksjoki S, Kujari H, Vuorio E, Anttila L. Expressionpatterns of cathepsins B, H, K, L and S in the human endometrium.Mol Hum Reprod. 2001;7(1):73-78.
67. McQuibban GA, Gong JH, Tam EM, et al. Inflammation dampenedby gelatinase A cleavage of monocyte chemoattractant protein-3.Science. 2000;289(5482):1202-1206.
68. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinalalpha-defensin activation by the metalloproteinase matrilysin in innatehost defense. Science. 1999;286(5437):113-117.
69. Zhang K, McQuibban GA, Silva C, et al. HIV-induced metalloproteinaseprocessing of the chemokine stromal cell derived factor-1 causesneurodegeneration. Nat Neurosci. 2003;6(10):1064-1071.
70. Hasan L, Mazzucchelli L, Liebi M, et al. Function of liver activationregulatedchemokine/CC chemokine ligand 20 is differently affectedby cathepsin B and cathepsin D processing. J Immunol. 2006;176(11):6512-6522.
71. Taggart CC, Greene CM, Smith SG, et al. Inactivation of human betadefensins2 and 3 by elastolytic cathepsins. J Immunol. 2003;171(2):931-937.
72. Lim JK, Lu W, Hartley O, DeVico AL. N-terminal proteolytic processingby cathepsin G converts RANTES/CCL5 and related analogs into atruncated 4-68 variant. J Leukoc Biol. 2006;80(6):1395-1404.
73. Cummins JE, Christensen L, Lennox JL, et al. Mucosal innateimmune factors in the female genital tract are associated with vaginalHIV-1 shedding independent of plasma viral load. AIDS Res HumRetroviruses. 2006;22(8):788-795.
74. El Messaoudi K, Thiry L, Van Tieghem N, et al. HIV-1 infectivityand host range modification by cathepsin D present in human vaginalsecretions. AIDS. 1999;13(3):333-339.
75. El Messaoudi K, Thiry LF, Liesnard C, et al. A human milk factor susceptibleto cathepsin D inhibitors enhances human immunodeficiencyvirus type 1 infectivity and allows virus entry into a mammaryepithelial cell line. J Virol. 2000;74(2):1004-1007.
76. Shaw JL, Diamandis EP. Regulation of human tissue kallikrein-relatedpeptidase expression by steroid hormones in 32 cell lines. Biol Chem.2008;389(11):1409-1419.
77. Shaw JL, Petraki C, Watson C, Bocking A, Diamandis EP. Role oftissue kallikrein-related peptidases in cervical mucus remodeling andhost defense. Biol Chem. 2008;389(12):1513-1522.
78. Steinstraesser L, Tippler B, Mertens J, et al. Inhibition of early stepsin the lentiviral replication cycle by cathelicidin host defense peptides.Retrovirology. 2005;2:2.
79. Yamasaki K, Schauber J, Coda A, et al. Kallikrein-mediated proteolysisregulates the antimicrobial effects of cathelicidins in skin. FASEB J.2006;20(12):2068-2080.
80. Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptorspecificity and function of the chemokine RANTES (regulated onactivation, normal T cell expressed and secreted) by dipeptidylpeptidase IV (CD26)-mediated cleavage. J Exp Med. 1997;186(11):1865-1872.
81. Shioda T, Kato H, Ohnishi Y, et al. Anti-HIV-1 and chemotacticactivities of human stromal cell-derived factor 1alpha (SDF-1alpha) andSDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediatedcleavage. Proc Natl Acad Sci U S A. 1998;95(11):6331-6336.
82. Ansari AW, Heiken H, Moenkemeyer M, Schmidt RE. Dichotomouseffects of C-C chemokines in HIV-1 pathogenesis. Immunol Lett. 2007;110(1):1-5.
83. Garzino-Demo A. Chemokines and defensins as HIV suppressivefactors: an evolving story. Curr Pharm Des. 2007;13(2):163-172.
84. Ghosh M, Shen Z, Fahey JV, et al. Trappin-2/Elafin: a novel innateanti-HIV-1 molecule of the human female reproductive tract.Immunology. In press 2009.
85. Iqbal SM, Ball TB, Levinson P, et al. Elevated elafin/trappin-2 inthe female genital tract is associated with protection against HIVacquisition. AIDS. 2009;23(13):1669-1677.
86. Moreau T, Baranger K, Dade S, et al. Multifaceted roles of humanelafin and secretory leukocyte proteinase inhibitor (SLPI), two serineprotease inhibitors of the chelonianin family. Biochimie. 2008;90(2):284-295.
87. Asin SN, Heimberg AM, Eszterhas SK, Rollenhagen C, Howell AL.Estradiol and progesterone regulate HIV type 1 replication in peripheralblood cells. AIDS Res Hum Retroviruses. 2008;24(5):701-716.
88. Katagiri D, Hayashi H, Victoriano AF, Okamoto T, Onozaki K.Estrogen stimulates transcription of human immunodeficiency virustype 1 (HIV-1). Int Immunopharmacol. 2006;6(2):170-181.
89. Lavreys L, Baeten JM, Kreiss JK, et al. Injectable contraceptive use andgenital ulcer disease during the early phase of HIV-1 infection increaseplasma virus load in women. J Infect Dis. 2004;189(2):303-311.
90. Lavreys L, Baeten JM, Martin HL Jr, et al. Hormonal contraceptionand risk of HIV-1 acquisition: results of a 10-year prospective study.AIDS. 2004;18(4):695-697.
91. Plummer FA, Simonsen JN, Cameron DW, et al. Cofactors in malefemalesexual transmission of human immunodeficiency virus type 1.J Infect Dis. 1991;163(2):233-239.
92. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonalcontraception, and the immunobiology of human immunodeficiencyvirus-1 infection. Endocr Rev. 2010;31(1):79-97.
93. Kiddugavu M, Makumbi F, Wawer MJ, et al. Hormonal contraceptiveuse and HIV-1 infection in a population-based cohort in Rakai, Uganda.AIDS. 2003;17(2):233-240.
94. Miller L, Patton DL, Meier A, et al. Depomedroxyprogesteroneinducedhypoestrogenism and changes in vaginal flora and epithelium.Obstet Gynecol. 2000;96(3):431-439.
95. Smith CL, Wolford RG, O'Neill TB, Hager GL. Characterizationof transiently and constitutively expressed progesterone receptors:evidence for two functional states. Mol Endocrinol. 2000;14(7):956-971.
96. Sheffield JS, Wendel GD Jr, McIntire DD, Norgard MV. The effect ofprogesterone levels and pregnancy on HIV-1 coreceptor expression.Reprod Sci. 2009;16(1):20-31.
97. de Jong MA, de Witte L, Oudhoff MJ, et al. TNF-alpha and TLRagonists increase susceptibility to HIV-1 transmission by humanLangerhans cells ex vivo. J Clin Invest. 2008;118(10):3440-3452.
98. Spear GT, al-Harthi L, Sha B, et al. A potent activator of HIV-1replication is present in the genital tract of a subset of HIV-1-infectedand uninfected women. AIDS. 1997;11(11):1319-1326.
99. Spear GT, Zariffard MR, Chen HY, et al. Positive association betweenHIV RNA and IL-6 in the genital tract of Rwandan women. AIDS ResHum Retroviruses. 2008;24(7):973-976.
100. Stoddard E, Ni H, Cannon G, et al. gp340 promotes transcytosis ofhuman immunodeficiency virus type 1 in genital tract-derived cell linesand primary endocervical tissue. J Virol. 2009;83(17):8596-8603.
101. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of humanimmunodeficiency virus type 1 RNA levels in blood and the femalegenital tract. J Infect Dis. 1999;179(4):871-882.
102. Uvin SC, Caliendo AM. Cervicovaginal human immunodeficiencyvirus secretion and plasma viral load in human immunodeficiencyvirus-seropositive women. Obstet Gynecol. 1997;90(5):739-743.
103. Saracino A, Di Stefano M, Fiore JR, et al. Frequent detection of HIV-1RNA but low rates of HIV-1 isolation in cervicovaginal secretionsfrom infected women. New Microbiol. 2000;23(1):79-83.
104. Coombs RW, Wright DJ, Reichelderfer PS, et al. Variation of humanimmunodeficiency virus type 1 viral RNA levels in the female genitaltract: implications for applying measurements to individual women.J Infect Dis. 2001;184(9):1187-1191.
105. Coleman JS, Hitti J, Bukusi EA, et al. Infectious correlates ofHIV-1 shedding in the female upper and lower genital tracts. AIDS.2007;21(6):755-759.
106. Spear GT, St John E, Zariffard MR. Bacterial vaginosis and humanimmunodeficiency virus infection. AIDS Res Ther. 2007;4:25.
107. St John E, Mares D, Spear GT. Bacterial vaginosis and host immunity.Curr HIV/AIDS Rep. 2007;4(1):22-28.
108. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction ofHIV-1 replication in latently infected CD4+ T cells using a combinationof cytokines. J Exp Med. 1998;188(1):83-91.
109. Poli G, Bressler P, Kinter A, et al. Interleukin 6 induces humanimmunodeficiency virus expression in infected monocytic cells aloneand in synergy with tumor necrosis factor alpha by transcriptional andpost-transcriptional mechanisms. J Exp Med. 1990;172(1):151-158.
110. Poli G, Kinter A, Justement JS, et al. Tumor necrosis factoralpha functions in an autocrine manner in the induction of humanimmunodeficiency virus expression. Proc Natl Acad Sci U S A.1990;87(2):782-785.
111. Poli G, Kinter AL, Fauci AS. Interleukin 1 induces expression of thehuman immunodeficiency virus alone and in synergy with interleukin6 in chronically infected U1 cells: inhibition of inductive effectsby the interleukin 1 receptor antagonist. Proc Natl Acad Sci U S A.1994;91(1):108-112.
112. Hashemi FB, Mollenhauer J, Madsen LD, et al. Myeloid-related protein(MRP)-8 from cervico-vaginal secretions activates HIV replication.AIDS. 2001;15(4):441-449.
113. Levinson P, Kaul R, Kimani J, et al. Levels of innate immune factorsin genital fluids: association of alpha defensins and LL-37 withgenital infections and increased HIV acquisition. AIDS. 2009;23(3):309-317.
114. Bretschneider N, Kangaspeska S, Seifert M, et al. E2-mediatedcathepsin D (CTSD) activation involves looping of distal enhancerelements. Mol Oncol. 2008;2(2):182-190.
115. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM. Cationicpolypeptides are required for anti-HIV-1 activity of human vaginalfluid. J Immunol. 2005;175(11):7560-7567.